Andromeda Surgical (LinkedIn) · Jul 2026
Company said it received a Medical Device Licence from Health Canada, making Canada the second launch country after New Zealand, and said Canadian hospitals are ready for live cases.
Autonomous surgical robots
Public company, workplace, funding, and market signals
Andromeda Surgical is a South San Francisco medical technology company building an AI-guided, software-first surgical robotics platform for endourology, starting with HoLEP/RoLEP and aiming to expand into additional procedures and specialties.
Primary product
AI-guided surgical platform for endourology (RoLEP/HoLEP)
Founded
2023
Headquarters
South San Francisco, California, United States
Team size
10-20
Work style
Onsite
Industry
Medical Technology
Sub-industry
Surgical robotics / autonomous surgical robots
Offices
17 jobs at Andromeda Surgical
Business model
Stage
Series A
Total raised
$21.1M
Latest round
Series A · Apr 2026
Latest amount
$14.8M
Leadership
Co-founder & CEO
Co-founder & CTO
Head of Clinical
Quality and Regulatory Lead
Public hiring and company posts describe a small, technical, fast-moving team that values high agency, first principles thinking, bias toward action, comfort with ambiguity, and software-first execution.
Work style
Onsite
Compensation
Public YC job postings show engineering roles around $140k-$250k salary with roughly 0.80%-1.50% equity; broader compensation and benefits policy is not publicly detailed.
Pricing
Enterprise contact-sales; hardware sales plus software/platform licensing or subscription
Differentiators
Technology
Customers
Competitors
Estimated revenue
≈$1.5M ARR (public estimate)
Estimated monthly visits
3.1K
Traffic estimate as of Oct 2025
Andromeda Surgical (LinkedIn) · Jul 2026
Company said it received a Medical Device Licence from Health Canada, making Canada the second launch country after New Zealand, and said Canadian hospitals are ready for live cases.
Andromeda Surgical (LinkedIn) · May 2026
Company said New Zealand is the first country where it is cleared to launch commercially and that it is pursuing additional clearances in the US, Canada, Brazil, LatAm, and the EU.
Andromeda Surgical (LinkedIn) · Apr 2026
Company said its clinical trial showed learning-curve improvements, with average enucleation times improving from 270 minutes at the start of 2025 to 90 minutes by year-end, and it is targeting sub-hour cases.
GlobeNewswire / Andromeda Surgical · Mar 2025
The company announced strategic partnerships to integrate Richard Wolf visualization and Quanta System holmium laser technology into its robotic platform and said it had completed 15 procedures in Chile and New Zealand in the ASTRA study.
PR Newswire / Andromeda Surgical · Dec 2024
Andromeda said Dr. Cristián Trucco performed the first robotic-assisted HoLEP procedure in Santiago, Chile, launching the ASTRA clinical trial and beginning the company's commercial-translation path.